Financial Data and Key Metrics Changes - Revenue increased by 3% at constant currency, totaling $10.7 billion, while net profit after tax (NPAT) was $2.25 billion, at the top end of financial guidance [9][46] - Gross profit remained steady at $5.8 billion, but EBIT decreased by 8% to $2.9 billion due to increased R&D investments [46][50] - Cash flow from operations fell by 27% to $2.6 billion, primarily due to a significant increase in inventory costs related to plasma [46][52] Business Line Data and Key Metrics Changes - CSL Behring's total revenue rose by 2% at constant currency, with immunoglobulin sales declining by 3% due to lower plasma collections [49][16] - IDELVION, a hemophilia B product, saw a strong performance with sales up 20%, while specialty products grew significantly, with HAEGARDA up 5% [13][25] - CSL Seqirus reported total revenue growth of 13%, driven by a 16% increase in seasonal influenza vaccine sales, particularly FLUAD, which rose by 41% [42][50] Market Data and Key Metrics Changes - North America remained the largest market for CSL Behring, accounting for 49% of total revenue, while Asia-Pacific grew by 21% due to strong albumin demand in China [17][21] - European revenue declined by 5%, impacted by immunoglobulin supply tightness [17] - The overall plasma collections increased by 24% year-on-year, indicating a recovery in supply [10][30] Company Strategy and Development Direction - The acquisition of Vifor Pharma is expected to enhance CSL's portfolio in renal disease and iron deficiency, with strong cash flow generation anticipated [5][6] - The company is focused on executing its 2030 strategy while continuing to invest in R&D for sustainable growth [8][11] - CSL aims to maintain its A credit ratings while expanding its strategic horizons post-acquisition [6][54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of plasma collections and anticipated strong sales growth for immunoglobulin and albumin products [58] - The company expects revenue growth of 7% to 11% for fiscal year 2023, with NPAT projected between $2.4 billion and $2.5 billion [60] - Challenges such as inflationary pressures and staffing constraints were acknowledged, but the fundamentals of the business were deemed strong [59][60] Other Important Information - The company maintained its final dividend at $1.18 per share, translating to a total of $2.22 per share for the financial year [48] - CSL's sustainability strategy includes a target to reduce carbon emissions by 40% by 2030 [54][55] Q&A Session Summary Question: Organic basis for EBIT or NPAT amidst non-recurring items - Management indicated that the forward guidance of $2.4 billion to $2.5 billion NPAT reflects the underlying performance of the legacy business, excluding Vifor-related costs [63][64] Question: Green shoots in plasma business and exit rates - Management noted that the exit rate in the second half was a good indicator of improvement, despite challenges from COVID variants affecting staffing and donor availability [66] Question: Outlook for immunoglobulin and CIDP indication - Management remains bullish on immunoglobulin as a standard of care, indicating that new products may not significantly impact the existing market share [69][70] Question: Confidence in maintaining albumin sales amidst competitive pressures - Management expressed confidence in albumin demand, particularly in China, while acknowledging pricing pressures due to increased competition [73]

T +613 9389 1911 F +613 9389 1434 www.csl.com.au ASX Announcement For immediate release 17 August 2022 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2022 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at https://edge.mediaserver.com/mmc/p/4vrmr7kw. Please note that this link will expi ...

CSL Limited (OTCQX:CSLLY) Q2 2022 Earnings Conference Call February 15, 2022 7:00 PM ET Company Participants Paul Perreault - MD, CEO & Executive Director Joy Linton - CFO Mark Dehring - Head, IR Conference Call Participants Lyanne Harrison - Bank of America Merrill Lynch David Low - JPMorgan Chase & Co. Chris Cooper - Goldman Sachs Group Gretel Janu - Crédit Suisse Andrew Goodsall - MST Marquee Saul Hadassin - Barrenjoey David Stanton - Jefferies Steven Wheen - Jarden Limited Sean Laaman - Morgan Stanley C ...

T +613 9389 1911 F +613 9389 1434 www.csl.com.au ASX Announcement For immediate release 18 August 2021 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2021 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at https://csl.webcastcloud.com/event?eventid=cc1ba0b2-0ddc-4c36-a8bcda89aec8c6d8. P ...

CSL Limited (OTCQX:CSLLY) Q4 2021 Earnings Conference Call August 17, 2021 8:00 PM ET Company Participants Mark Dehring - Vice President, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Steven Wheen - Jarden Chris Cooper - Goldman Sachs Andrew Goodsall - MST Marquee Saul Hadassin - Beringer Capital David Low - JPMorgan David Bailey - Macquarie Gretel Janu - Credit Suisse Dave Stanton - Jefferies J ...

CSL Limited (OTCQX:CSLLY) Q2 2021 Earnings Conference Call February 17, 2021 6:00 PM ET Company Participants Mark Dehring - Vice President, Investor Relations Paul Perreault - Chief Executive Officer John Levy - Interim Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America David Low - JPMorgan Andrew Goodsall - MST Steven Wheen - Jarden Saul Hadassin - UBS Chris Cooper - Goldman Sachs David Stanton - Jefferies John Deakin-Bell - Citigroup Sean Laaman - Morgan Stanley David B ...

T +613 9389 1911 F +613 9389 1434 www.csl.com.au ASX Announcement For immediate release 18 February 2021 RESULTS PRESENTATION FOR THE HALF YEAR ENDED 31 DECEMBER 2020 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer and the Interim Chief Financial Officer shortly. The briefing will be webcast and can be accessed in the "Investor" section of CSL's website (www.CSL.com). Authorised ...

CSF | --- | --- | --- | --- | --- | |-------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | CSL Limited | | | | | | 2020 Full Year Results | | | | | | 19 th August, 2020 | | | | | Paul Perreault CEO and MD David Lamont CFO FORWARD LOOKING STATEMENTS 2 Legal Notice The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) fina ...

CSL Limited (OTCQX:CSLLY) Q4 2020 Earnings Conference Call August 18, 2020 9:00 PM ET Mark Dehring Company Participants | --- | |----------------------------------------------------------------| | | | | | Mark Dehring - VP, IR | | Paul Perreault - CEO | | David Lamont - CFO | | Conference Call Participants | | Chris Cooper - Goldman Sachs Lyanne Harrison - Bank of America | | David Low - JPMorgan | | Sean Laaman - Morgan Stanley | | Andrew Goodsall - MST Marquee | | Steve Wheen - Evans & Partners | | David ...